Discovery of dipeptides with high affinity to the specific binding site for substance P1-7

Journal of Medicinal Chemistry

Volumn 53, Issue 6, 2010, Pages 2383-2389

  Fransson, Rebecca ^a   Botros, Milad ^a   Sköld, Christian ^a   Nyberg, Fred ^a   Lindeberg, Gunnar ^a   Hallberg, Mathias ^a   Sandström, Anja ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDE DERIVATIVE; ENDOMORPHIN 2; SUBSTANCE P [1-7];

ANIMAL TISSUE; ARTICLE; BINDING SITE; DRUG PROTEIN BINDING; MALE; MOUSE; NONHUMAN;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; DIPEPTIDES; DRUG DISCOVERY; HUMANS; KINETICS; MALE; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-3; SPINAL CORD; SUBSTANCE P;

EID: 77949849922     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901352b     Document Type: Article

References (35)

1. Von Euler, U. S.; Gaddum, J. H. An unidentified depressor substance in certain tissue extracts. J. Physiol. 1931, 72, 74-87.
2. Zubrzycka, M.; Janecka, A. Substance P: transmitter of nociception (Minireview). Endocr. Regul. 2000, 34, 195-201.
3. Kramer, M. S.; Cutler, N.; Feighner, J.; Shrivastava, R.; Carman, J.; Sramek, J. J.; Reines, S. A.; Liu, G.; Snavely, D.; WyattKnowles, E.; Hale, J. J.; Mills, S. G.; MacCoss, M.; Swain, C. J.; Harrison, T.; Hill, R. G.; Hefti, F.; Scolnick, E. M.; Cascieri, M. A.; Chicchi, G. G.; Sadowski, S.; Williams, A. R.; Hewson, L.; Smith, D.; Carlson, E. J.; Hargreaves, R. J.; Rupniak, N. M. J. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998, 281, 1640-1645.
4. De Araujo, J. E.; Huston, J. P.; Brandao, M. L. Opposite effects of substance P fragments C (anxiogenic) and N (anxiolytic) injected into dorsal periaqueductal gray. Eur. J. Pharmacol. 2001, 432, 43-51.
5. Campos, D.; Pereira, J. R.; Reinhardt, R. R.; Carracedo, C.; Poli, S.; Vogel, C.; Martinez-Cedillo, J.; Erazo, A.; Wittreich, J.; Eriksson, L.-O.; Carides, A. D.; Gertz, B. J. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J. Clin. Oncol. 2001, 19, 1759-1767.
6. Hallberg, M.; Nyberg, F. Neuropeptide conversion to bioactive fragments-an important pathway in neuromodulation. Curr. Protein Peptide Sci. 2003, 4, 31-44.
7. Lee, C.-M.; Sandberg, B. E. B.; Hanley, M. R.; Iversen, L. L. Purification and characterization of a membrane-bound substance P-degrading enzyme from human brain. Eur. J. Biochem. 1981, 114, 315-327.
8. Sakurada, T.; Le Greves, P.; Stewart, J.; Terenius, L. Measurement of substance P metabolites in rat CNS. J. Neurochem. 1985, 44, 718-722.
9. Sakurada, C.; Watanabe, C.; Sakurada, T. Occurrence of substance P(1-7) in the metabolism of substance P and its antinociceptive activity at the mouse spinal cord level. Methods Find. Exp. Clin. Pharmacol. 2004, 26, 171-176.
10. Wiktelius, D.; Khalil, Z.; Nyberg, F. Modulation of peripheral inflammation by the substance P N-terminal metabolite substance P1-7. Peptides 2006, 27, 1490-1497.
11. Kreeger, J. S.; Larson, A. A. Substance P-(1-7), a substance P metabolite, inhibits withdrawal jumping in morphine-dependent mice. Eur. J. Pharmacol. 1993, 238, 111-115.
12. Zhou, Q.; Frandberg, P.-A.; Kindlundh, A. M. S.; Le Greves, P.; Nyberg, F. Substance P(1-7) affects the expression of dopamine D2 receptor mRNA in male rat brain during morphine withdrawal. Peptides 2003, 24, 147-153.
13. Tomaz, C.; Silva, A. C.; Nogueira, P. J. Long-lasting mnemotropic effect of substance P and its N-terminal fragment (SP1-7) on avoidance learning. Braz. J. Med. Biol. Res. 1997, 30, 231-233.
14. Igwe, O. J.; Kim, D. C.; Seybold, V. S.; Larson, A. A. Specific binding of substance P aminoterminal heptapeptide [SP(1-7)] to mouse brain and spinal cord membranes. J. Neurosci. 1990, 10, 3653-3663.
15. Botros, M.; Hallberg, M.; Johansson, T.; Zhou, Q.; Lindeberg, G.; Frändberg, P.-A.; Toemboely, C.; Toth, G.; Le Greves, P.; Nyberg, F. Endomorphin-1 and endomorphin-2 differentially interact with specific binding sites for substance P (SP) aminoterminal SP1-7 in the rat spinal cord. Peptides 2006, 27, 753-759.
16. Botros, M.; Johansson, T.; Zhou, Q.; Lindeberg, G.; Tomboly, C.; Toth, G.; Le Greves, P.; Nyberg, F.; Hallberg, M. Endomorphins interact with the substance P (SP) aminoterminal SP1-7 binding in the ventral tegmental area of the rat brain. Peptides 2008, 29, 1820-1824.
17. 7 attenuates the expression of naloxone-precipitated withdrawal in morphine dependent rats. Peptides 2009, 30, 2418-2422.
18. Betancur, C.; Azzi, M.; Rostene, W. Nonpeptide antagonists of neuropeptide receptors: tools for research and therapy. Trends Pharmacol. Sci. 1997, 18, 372-386.
19. Hökfelt, T.; Bartfai, T.; Bloom, F. Neuropeptides: opportunities for drug discovery. Lancet Neurol. 2003, 2, 463-472.
20. Hökfelt, T.; Broberger, C.; Xu, Z. Q. D.; Sergeyev, V.; Ubink, R.; Diez, M. Neuropeptides- an overview. Neuropharmacology 2000, 39, 1337-1356.
21. Fransson, R.; Botros, M.; Nyberg, F.; Lindeberg, G.; Sandström, A.; Hallberg, M. Small peptides mimicking substance P (1 -7) and encompassing a C-terminal amide functionality. Neuropeptides 2008, 42, 31-37.
22. Zadina, J. E.; Hackler, L.; Ge, L.-J.; Kastin, A. J. A potent and selective endogenous agonist for the micro-opiate receptor. Nature 1997, 386, 499-502.
23. Okada, Y.; Fujita, Y.; Motoyama, T.; Tsuda, Y.; Yokoi, T.; Li, T.; Sasaki, Y.; Ambo, A.; Jinsmaa, Y.; Bryant Sharon, D.; Lazarus Lawrence, H. Structural studies of [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues: enhanced activity and cis orientation of the Dmt-Pro amide bond. Biorg. Med. Chem. 2003, 11, 1983-1994.
24. Kruszynski, R.; Fichna, J.; do-Rego, J.-C.; Janecki, T.; Kosson, P.; Pakulska, W.; Costentin, J.; Janečka, A. Synthesis and biological activity of N-methylated analogs of endomorphin-2. Bioorg. Med. Chem. 2005, 13, 6113-6717.
25. Fichna, J.; Janecka, A.; Costentin, J.; Do Rego, J.-C. The endomorphin system and its evolving neurophysiological role. Pharmacol. Rev. 2007, 59, 88-123.
26. Muthas, D.; Lek, P. M.; Nurbo, J.; Karlen, A.; Lundstedt, T. Focused hierarchical design of peptide libraries-follow the lead. J. Chemom. 2007, 21, 486-495.
27. Boden, P.; Eden, J. M.; Hodgson, J.; Horwell, D. C.; Hughes, J.; McKnight, A. T.; Lewthwaite, R. A.; Pritchard, M. C.; Raphy, J.; Meecham, K.; Ratcliffe, G. S.; Suman-Chauhan, N.; Woodruff, G. N. Use of a dipeptide chemical library in the development of nonpeptide tachykinin NK3 receptor selective antagonists. J. Med. Chem. 1996, 39, 1664-1675.
28. Ondetti, M. A.; Rubin, B.; Cushman, D. W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977, 196, 441-444.
29. Boden, P.; Eden, J. M.; Hodgson, J.; Horwell, D. C.; Howson, W.; Hughes, J.; McKnight, A. T.; Meecham, K.; Pritchard, M. C.; et al. The rational development of small molecule tachykinin NK3 receptor selective antagonists-the utilization of a dipeptide chemical library in drug design. Bioorg. Med. Chem. Lett. 1994, 4, 1679-1684.
30. Boden, P.; Eden, J. M.; Hodgson, J.; Horwell, D. C.; Pritchard, M. C.; Raphy, J.; Suman-Chauhan, N. The development of a novel series of nonpeptide tachykinin NK3 receptor selective antagonists. Bioorg. Med. Chem. Lett. 1995, 5, 1773-1778.
31. Sakurada, C.; Sakurada, S.; Hayashi, T.; Katsuyama, S.; Tan-No, K.; Sakurada, T. Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study. Biochem. Pharmacol. 2003, 66, 653-661.
32. Sanderson Nydahl, K.; Skinner, K.; Julius, D.; Basbaum Allan, I. Co-localization of endomorphin-2 and substance P in primary afferent nociceptors and effects of injury: a light and electron microscopic study in the rat. Eur. J. Neurosci. 2004, 19, 1789-1799.
33. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-1215
34. Anthes, J. C.; Chapman, R. W.; Richard, C.; Eckel, S.; Corboz, M.; Hey, J. A.; Fernandez, X.; Greenfeder, S.; McLeod, R.; Sehring, S.; Rizzo, C.; Crawley, Y.; Shih, N. Y.; Piwinski, J.; Reichard, G.; Ting, P.; Carruthers, N.; Cuss, F. M.; Billah, M.; Kreutner, W.; Egan, R. W. SCH 206272: a potent, orally active tachykinin NK1, NK2, and NK3 receptor antagonist. Eur. J. Pharmacol. 2002, 450, 191-202.
35. Heuillet, E.; Menager, J.; Fardin, V.; Flamand, O.; Bock, M.; Garret, C.; Crespo, A.; Fallourd, A. M.; Doble, A. Characterization of a Human Nk1 Tachykinin Receptor in the Astrocytoma Cell-Line U-373 Mg. J. Neurochem. 1993, 60, 868-876.